(Stroke. 1999;30:993-996.)
© 1999 American Heart Association, Inc.
Original Contributions |
Controlled Safety Study of a Hemoglobin-Based Oxygen Carrier, DCLHb, in Acute Ischemic Stroke
From the Department of Neurology, University Hospital Dijkzigt, Rotterdam, the Netherlands (R.S., A.D.W., P.J.K.); the Department of Neurology, Gasthuisberg University Hospital, Leuven, Belgium (H.C.); the Department of Neurology, University Hospital Heidelberg, Heidelberg, Germany (W.H.); the Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland (M.K.); and Baxter Healthcare Corporation, Route 120 & Wilson Road, Round Lake, Ill (R.J.P., K.N.S.).
Correspondence to Prof Peter J. Koudstaal, MD, Department of Neurology, University Hospital Rotterdam, PO Box 2040, 3000 CA Rotterdam, Netherlands. E-mailKoudstaal{at}neur.azr.nl
Background and Purpose—Diaspirin cross-linked hemoglobin (DCLHb) is a purified, cell-free human hemoglobin solution. In animal stroke models its use led to a significant reduction in the extent of brain injury. The primary objective of this study was to evaluate the safety of DCLHb in patients with acute ischemic stroke.
Methods—DCLHb or saline was administered to 85 patients with acute ischemic stroke in the anterior circulation, within 18 hours of onset of symptoms, in a multicenter, randomized, single-blind, dose-finding, controlled safety trial, consisting of 3 parts: 12 doses of 25, 50, and 100 mg/kg DCLHb over 72 hours.
Results—DCLHb caused a rapid rise in mean arterial blood pressure. The pressor effect was not accompanied by complications or excessive need for antihypertensive treatment. Two patients in the 100 mg/kg group had adverse events that were possibly drug related: one suffered fatal brain and pulmonary edema, the other transient renal and pancreatic insufficiency. Multivariate logistic regression analysis showed that a severe stroke at baseline and treatment with DCLHb (OR, 4.0; CI, 1.4 to 12.0) were independent predictors of a worse outcome (Rankin Scale score of 3 to 6) at 3 months.
Conclusions—Outcome scale scores were worse in the DCLHb group, and more serious adverse events and deaths occurred in DCLHb-treated patients than in control patients. We recommend that additional safety studies be performed, preferably with a second generation, genetically engineered hemoglobin.
Key Words: blood substitutes • hemoglobins • safety • stroke, acute • stroke, ischemic
This article has been cited by other articles:
 |
|
 |
|
  C. M. Geeganage and P. M.W. Bath Relationship Between Therapeutic Changes in Blood Pressure and Outcomes in Acute Stroke: A Metaregression Hypertension, October 1, 2009; 54(4): 775 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Cao, L.-C. Wang, H. Kwansa, R. J. Roman, D. R. Harder, and R. C. Koehler Endothelin rather than 20-HETE contributes to loss of pial arteriolar dilation during focal cerebral ischemia with and without polymeric hemoglobin transfusion Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2009; 296(5): R1412 - R1418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 The Optimising the Analysis of Stroke Trials (OAST Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors? Stroke, March 1, 2009; 40(3): 888 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Mito, M. Nemoto, H. Kwansa, K. Sampei, M. Habeeb, S. J. Murphy, E. Bucci, and R. C. Koehler Decreased Damage From Transient Focal Cerebral Ischemia by Transfusion of Zero-Link Hemoglobin Polymers in Mouse Stroke, January 1, 2009; 40(1): 278 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Fergusson and L. McIntyre The Future of Clinical Trials Evaluating Blood Substitutes JAMA, May 21, 2008; 299(19): 2324 - 2326. [Full Text] [PDF]
|
|
|
|
|
|
C. Natanson, S. J. Kern, P. Lurie, S. M. Banks, and S. M. Wolfe Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death: A Meta-analysis JAMA, May 21, 2008; 299(19): 2304 - 2312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The Optimising Analysis of Stroke Trials (OAST) Co Can We Improve the Statistical Analysis of Stroke Trials?: Statistical Reanalysis of Functional Outcomes in Stroke Trials * OAST Supplemental Appendix I: Statistical Tests Compared (see Table I) * OAST Supplemental Appendix II: Supplementary Analyses * OAST Supplemental Appendix III: Trial Data (see Tables II and III) * OAST Supplemental Appendix IV: Results (see Table IV) Stroke, June 1, 2007; 38(6): 1911 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Kawaguchi, D. Fukumoto, M. Haida, Y. Ogata, M. Yamano, and H. Tsukada Liposome-Encapsulated Hemoglobin Reduces the Size of Cerebral Infarction in the Rat: Evaluation With Photochemically Induced Thrombosis of the Middle Cerebral Artery Stroke, May 1, 2007; 38(5): 1626 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Mistri, T. G. Robinson, and J. F. Potter Pressor Therapy in Acute Ischemic Stroke: Systematic Review Stroke, June 1, 2006; 37(6): 1565 - 1571. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nemoto, T. Mito, W. S Brinigar, C. Fronticelli, and R. C. Koehler Salvage of focal cerebral ischemic damage by transfusion of high O2-affinity recombinant hemoglobin polymers in mouse J Appl Physiol, May 1, 2006; 100(5): 1688 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Sampei, J. A. Ulatowski, Y. Asano, H. Kwansa, E. Bucci, and R. C. Koehler Role of nitric oxide scavenging in vascular response to cell-free hemoglobin transfusion Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1191 - H1201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Rother, L. Bell, P. Hillmen, and M. T. Gladwin The Clinical Sequelae of Intravascular Hemolysis and Extracellular Plasma Hemoglobin: A Novel Mechanism of Human Disease JAMA, April 6, 2005; 293(13): 1653 - 1662. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Winslow, J. Lohman, A. Malavalli, and K. D. Vandegriff Comparison of PEG-modified albumin and hemoglobin in extreme hemodilution in the rat J Appl Physiol, October 1, 2004; 97(4): 1527 - 1534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Drobin, B. T. Kjellstrom, E. Malm, A. Malavalli, J. Lohman, K. D. Vandegriff, M. A. Young, and R. M. Winslow Hemodynamic response and oxygen transport in pigs resuscitated with maleimide-polyethylene glycol-modified hemoglobin (MP4) J Appl Physiol, May 1, 2004; 96(5): 1843 - 1853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. P. Adams Jr, R. J. Adams, T. Brott, G. J. del Zoppo, A. Furlan, L. B. Goldstein, R. L. Grubb, R. Higashida, C. Kidwell, T. G. Kwiatkowski, et al. Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association Stroke, April 1, 2003; 34(4): 1056 - 1083. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Semplicini, A. Maresca, G. Boscolo, M. Sartori, R. Rocchi, V. Giantin, P. L. Forte, and A. C. Pessina Hypertension in Acute Ischemic Stroke: A Compensatory Mechanism or an Additional Damaging Factor? Arch Intern Med, January 27, 2003; 163(2): 211 - 216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. D'Agnillo and A. I. Alayash Redox cycling of diaspirin cross-linked hemoglobin induces G2/M arrest and apoptosis in cultured endothelial cells Blood, December 1, 2001; 98(12): 3315 - 3323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bath, G. Boysen, G. Donnan, M. Kaste, K. R Lees, T. Olsen, K. Overgaard, P. Sandercock, and N.-G. Wahlgren Hypertension in Acute Stroke: What to Do? Stroke, July 1, 2001; 32 (7): 1697 - 1698. [Full Text] [PDF]
|
|
|
|
|
|
K. Uchino, D. Billheimer, and S. C. Cramer Entry Criteria and Baseline Characteristics Predict Outcome in Acute Stroke Trials Stroke, April 1, 2001; 32(4): 909 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Forrest, A. H. Chester, and D. Royston The Effects of Diaspirin Cross-Linked Hemoglobin on the Tone of Human Saphenous Vein Anesth. Analg., February 1, 2001; 92(2): 324 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. D'Agnillo and A. I. Alayash Interactions of hemoglobin with hydrogen peroxide alters thiol levels and course of endothelial cell death Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1880 - H1889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Tirilazad Mesylate in Acute Ischemic Stroke : A Systematic Review Stroke, September 1, 2000; 31(9): 2257 - 2265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rebel, J. A. Ulatowski, K. Joung, E. Bucci, R. J. Traystman, and R. C. Koehler Regional cerebral blood flow in cats with cross-linked hemoglobin transfusion during focal cerebral ischemia Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H832 - H841. [Abstract] [Full Text] [PDF]
|
|